MET and non-small cell lung carcinoma: On the other hand, frequencies of activating mutations in MET (METex14 and MET amplification), ERBB2, ROS1, and ALK, were significantly higher compared to PSC and non‐squamous NSCLC [48, 56], delineating possible genomic features of PSCC to the matching targeted therapies.